Renal denervation may improve treatment control rates for uncontrolled hypertension without increasing medication burden and could help reduce significant treatment disparities in the United States.
Does renal denervation improve hypertension control rates and reduce treatment disparities in patients with uncontrolled hypertension?
Expanding coverage and access to renal denervation may serve as an important tool to reduce significant racial and ethnic treatment disparities in uncontrolled hypertension.
PURPOSE OF REVIEW: To discuss available data on renal denervation (RDN) for treating hypertension and how expanding access to RDN may improve rates of controlled hypertension while helping address hypertension treatment disparities. RECENT FINDINGS: RDN is an FDA-approved procedure for the treatment of patients with confirmed uncontrolled hypertension, with proven efficacy and safety in randomized sham-controlled trials. Centers for Medicare & Medicaid Services completed a national coverage analysis for RDN coverage for the treatment of uncontrolled hypertension. By summarizing the available data on RDN and hypertension statistics among different race and ethnicities in the United States, our review highlights the potential for RDN to improve treatment control rates, without increasing medication burden. By expanding coverage for the procedure, RDN may be an important tool to reduce significant treatment disparities in hypertension.
Spiazzi et al. (2026) conducted a review in Hypertension. Renal denervation (RDN) was evaluated. Renal denervation may improve treatment control rates for uncontrolled hypertension without increasing medication burden and could help reduce significant treatment disparities in the United States.